Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.55 |
| ▸ | GPR119 | Q8TDV5 | 4/20 | 0.54 |
| ▸ | PDE4A | P27815 | 2/20 | 0.50 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.50 |
| ▸ | PDE4C | Q08493 | 2/20 | 0.50 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.50 |
| ▸ | KDM1A | O60341 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | PKM | P14618 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.48 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.47 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29826469 | 1.00 | MEN1 (0.55) | MEN1KMT2AGPR119PDE4APDE4B | |
| SCHEMBL5548433 | 0.93 | USP30 (0.53) | MEN1KMT2AGPR119PDE4APDE4B | |
| SCHEMBL5542864 | 0.93 | USP30 (0.53) | MEN1KMT2AGPR119PDE4APDE4B | |
| SCHEMBL24793303 | 0.88 | USP30 (0.48) | MEN1KMT2AGPR119PDE4BKDM4E | |
| SCHEMBL2969976 | 0.88 | GPR119 (0.56) | MEN1KMT2AGPR119PDE4APDE4B | |
| SCHEMBL30955036 | 0.88 | GPR119 (0.56) | MEN1KMT2AGPR119PDE4APDE4B | |
| SCHEMBL2979574 | 0.88 | GPR119 (0.54) | MEN1KMT2AGPR119PDE4APDE4B | |
| SCHEMBL15994319 | 0.87 | GPR119 (0.55) | MEN1KMT2AGPR119PDE4APDE4B | |
| SCHEMBL240683 | 0.86 | GPR119 (0.61) | KMT2AGPR119PDE4APDE4BPDE4C | |
| SCHEMBL2284947 | 0.85 | GPR119 (0.55) | MEN1KMT2AGPR119PDE4APDE4B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240067630-A1 | ARYL ETHER-SUBSTITUTED HETEROCYCLIC COMPOUNDS AS GLP1R AGONISTS | MINDRANK AI LTD. (CN) | 2024-02-29 | — | — | US | disclosed |
| US-20240067630-A1 | ARYL ETHER-SUBSTITUTED HETEROCYCLIC COMPOUNDS AS GLP1R AGONISTS | MINDRANK AI LTD. (CN) | 2024-02-29 | — | — | US | disclosed |
| CN-117242067-A | Novel aryl ether substituted heterocycles as GLP1R agonists | 杭州德睿智药科技有限公司 | 2023-12-15 | — | — | CN | disclosed |
| EP-2961741-B1 | NOVEL COMPOUNDS AS DUAL INHIBITORS OF PHOSPHODIESTERASES AND HISTONE DEACETYLASES | FUND PARA LA INVESTIG MEDICA APLICADA (ES) | 2017-04-05 | — | — | EP | disclosed |
| US-9573956-B2 | Compounds as dual inhibitors of phosphodiesterases and histone deacetylases | FUNDACIÓN PARA LA INVESTIGACIÓN MÉDICA APLICADA (ES) | 2017-02-21 | — | — | US | disclosed |
| US-20160002246-A1 | NOVEL COMPOUNDS AS DUAL INHIBITORS OF PHOSPHODIESTERASES AND HISTONE DEACETYLASES | FUNDACIÓN PARA LA INVESTIGACIÓN MÉDICA APLICADA (ES) | 2016-01-07 | — | — | US | disclosed |
| EP-2961741-A1 | NOVEL COMPOUNDS AS DUAL INHIBITORS OF PHOSPHODIESTERASES AND HISTONE DEACETYLASES | Fundacion para la Investigacion Medica Aplicada (ES) | 2016-01-06 | — | — | EP | disclosed |
| WO-2014131855-A1 | NOVEL COMPOUNDS AS DUAL INHIBITORS OF PHOSPHODIESTERASES AND HISTONE DEACETYLASES | FUNDACIÓN PARA LA INVESTIGACIÓN MÉDICA APLICADA (ES) | 2014-09-04 | — | — | WO | disclosed |
| US-20120321559-A1 | HEXAHYDRO-PYRROLO-ISOQUINOLINE COMPOUNDS | APODACA RICHARD (US) | 2012-12-20 | — | — | US | disclosed |
| US-8273762-B2 | Hexahydro-pyrrolo-isoquinoline compounds | JANSSEN PHARMACEUTICA NV (BE) | 2012-09-25 | — | — | US | disclosed |
| US-20100240648-A1 | HEXAHYDRO-PYRROLO-ISOQUINOLINE COMPOUNDS | JANSSEN PHARMACEUTICA NV (BE) | 2010-09-23 | — | — | US | disclosed |
| US-7754882-B2 | Hexahydro-pyrrolo-isoquinoline compounds | JANSSEN PHARMACEUTICA NV (BE) | 2010-07-13 | — | — | US | disclosed |
| EP-1893613-A1 | HEXAHYDRO-PYRROLO-ISOQUINOLINE COMPOUNDS FOR THE TREATMENT OF CNS DISORDERS | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-03-05 | — | — | EP | disclosed |
| WO-2006138604-A1 | HEXAHYDRO-PYRROLO-ISOQUINOLINE COMPOUNDS FOR THE TREATMENT OF CNS DISORDERS | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-12-28 | — | — | WO | disclosed |
| US-20060293316-A1 | HEXAHYDRO-PYRROLO-ISOQUINOLINE COMPOUNDS | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-12-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060293316-A1 | HEXAHYDRO-PYRROLO-ISOQUINOLINE COMPOUNDS | HRH3, HRH1, HRH4 | MEN1 3014/4885KMT2A 1059/4885GPR119 135/4885 |
| US-20100240648-A1 | HEXAHYDRO-PYRROLO-ISOQUINOLINE COMPOUNDS | HRH3, HRH1, HRH4 | MEN1 3014/4885KMT2A 1059/4885GPR119 135/4885 |
| US-20240067630-A1 | ARYL ETHER-SUBSTITUTED HETEROCYCLIC COMPOUNDS AS GLP1R AGONISTS | GLP1R, GIPR, GCGR | MEN1 1246/4885KMT2A 1759/4885GPR119 4/4885 |
| US-20120321559-A1 | HEXAHYDRO-PYRROLO-ISOQUINOLINE COMPOUNDS | HRH3, HRH1, HRH4 | MEN1 3014/4885KMT2A 1059/4885GPR119 135/4885 |
| US-20160002246-A1 | NOVEL COMPOUNDS AS DUAL INHIBITORS OF PHOSPHODIESTERASES AND HISTONE DEACETYLASES | PDE1A, HDAC1, HDAC2 | MEN1 4226/4885KMT2A 98/4885GPR119 1007/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.